Stock Report: Amarin Corp. PLC ADS (AMRN) Report Updated: May 20, 2013 | Print This Page
Report Features:
Stock Analysis
Rating: Monthly View
| A |  |
 |
|
|
|
|
|
|
|
|
|
 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B | ||||||||||||
| C | ||||||||||||
| D | ||||||||||||
| F | ||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Rating: Weekly View
| This Week: | F  no change |
|---|---|
| Last Week: | F no change |
| Two Weeks Ago: | F no change |
Company Profile
Amarin Corporation plc, a late-stage biopharmaceutical company, focuses on developing the treatment for cardiovascular disease in the field of lipid science. Its lead product candidate includes AMR101, a prescription-only omega-3 fatty acid comprising icosapent ethyl, or ethyl-EPA for the treatment of patients with very high triglyceride levels and high triglyceride levels or hypertriglyceridemia. The company, formerly known as Ethical Holdings plc, was founded in 1989 and is headquartered in Dublin, Ireland.
Recent News: Amarin Corp. PLC ADS
| 2012-10-23 07:30:06 | Amarin Announces Issuance of U.S. Patents 8,793,727 and 8,293,728 for Vascepa(TM) |
| 2012-10-11 09:00:04 | Free Reports on AuRico Gold, Amarin, Keryx, and Yum! Brands Provided by the Bedford Report |
| 2012-10-10 00:00:00 | Report of unscheduled material events or corporate changes - Form 8-K |
| 2012-09-14 00:00:00 | - Form CT ORDER |
| 2012-09-10 08:30:14 | Amarin Announces Notification of Patent Allowance for U.S. Application 13/349,150 Related to Vascepa(TM) and FDA Approved MARINE Indication |
ADVERTISEMENT
My Portfolios (View All)
Save your portfolio—or a few for that matter—and check up on your stocks 24/7! Log in here.
Louis Navellier's Portfolios
- Blue Chip GrowthTop blue chips
- Emerging GrowthTop small-caps
- Ultimate GrowthFastest-moving
- Platinum GrowthElite Model Portfolio
Most Popular Stocks
Daily Leader Boards
Louis' Weekly Ratings
ADVERTISEMENT